(Natural News) Cannabidiol (CBD) is one of the 113 organic compounds in the Cannabis sativa plant, commonly known as hemp. Previous studies on CBD have focused on its medicinal uses for pain relief, epileptic seizures, insomnia and Parkinson’s disease.
But a recent study from the University of North Carolina at Chapel Hill (UNC) found that CBD could also benefit children and adults suffering from Angelman syndrome (AS).
First author Bin Gu and his colleagues tested the effects of CBD on seizures, motor deficits and brain abnormalities in a mouse model of the said neurogenetic disorder.
Their experiments demonstrated that CBD treatment can reduce the severity of seizures in mice with AS. In addition, CBD also caused mild sedation and restored the mice’s normal brain rhythms.
Gu is hopeful that their findings, published in the Journal of Clinical Investigation, could inspire further research into the use of CBD as a treatment for seizures caused by AS and other neurological disorders.
CBD reduces seizures and causes mild sedation
AS is a rare neurogenetic disorder that occurs in one in 15,000 live births, or about 500,000 people around the globe. It tends to cause developmental problems that become noticeable when an infant reaches six to 12 months of age.
AS can also cause other abnormalities, such as seizures, balance disorders and speech problems. Because of the rare nature of AS, there is scant research on possible treatments and therapies.
Benjamin Philpot, the associate director of the UNC Neuroscience Center and the study’s senior author, said that there is an unmet need for better treatments for children suffering from the disorder. In response to this need, he and his colleagues created genetically modified mouse models of AS that they could use to find a possible treatment.
The researchers chose to test CBD because of its anti-epileptic properties. In 2018, the U.S. Food and Drug Administration approved the use of CBD as a treatment for seizures caused by two rare forms of epilepsy. (Related: Treating neurological disorders in children with oriental herbal medicine.)
To assess the effects of CBD on AS symptoms, the researchers injected the genetically-modified mice they created with various doses of CBD an hour prior to behavioral testing. Regardless of dose, CBD did not have a major impact on motor coordination or balance.
However, injection of a standard anti-convulsant dose of CBD caused mild sedation in the mice and reduced the severity of their experimentally triggered seizures. CBD also helped stabilize brain pulses linked to neural deficits and abnormalities.
These results expand the therapeutic spectrum of the anti-epileptic effects of CBD. The researchers also believe that their study could help address the need for better treatments for children with AS.
CBD reduces seizures and autism-like behaviors in a mouse model of another childhood brain disorder
This isn’t the first time that scientists attempted to assess the therapeutic effects of CBD on rare and less-studied neurological disorders.
In 2017, researchers from the University of Washington (UW) used CBD to treat mice with Dravet syndrome (DS), a severe type of epilepsy characterized by prolonged seizures that begin in the first year of life.
But unlike AS patients whose symptoms tend to improve with age, DS patients tend to suffer from worse intellectual impairments, autism-like behaviors and other debilitating neurological problems over time.
DS is also a rare and life-long condition that affects one in 20,000 to 40,000 people worldwide. Its drug-resistant nature has further complicated the development of treatments and therapies for it.
The UW researchers assessed the effects of CBD treatment on a mouse model of DS. Their experiments showed that high doses of CBD could reduce the severity, frequency and duration of DS-induced seizures.
In addition, mice treated with low doses of CBD spent more time interacting with other mice compared with the untreated mice, indicating an improvement of autism-like behaviors. However, this effect was lost at the higher doses needed to reduce seizures.
Nephi Stella, the founder of the UW Center for Cannabis Research and a member of the research team, said that their findings highlight the need for a treatment that could confer both benefits at once.
Nevertheless, the researchers noted that their findings contribute to the emerging data supporting the use of CBD in the treatment of drug-resistant and debilitating neurological conditions.
Read more about the medicinal uses of CBD at CBDs.news.